PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE

  • Authors:
    • R LENZI
    • MN RABER
    • D GRAVEL
    • P FROST
    • JL ABBRUZZESE
  • View Affiliations

  • Published online on: February 1, 1995     https://doi.org/10.3892/ijo.6.2.447
  • Pages: 447-450
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m(2) of 5-aza-CdR and 75 mg/m(2) of cDDP. A response rate of 17% (90% confidence interval (CI) = 0%-37%) was observed in patients with metastatic carcinoma of unknown primary (UPC). The 5-aza-CdR/cDDP combination was safely administered at doses mirroring concentrations that significantly lessen cDDP resistance of human ovarian cancer cells in vitro. While the observed response rate did not warrant further study in UPC, evaluation of this regimen should be considered in patients with cDDP-resistant ovarian cancer.

Related Articles

Journal Cover

February 1995
Volume 6 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
LENZI, R., RABER, M., GRAVEL, D., FROST, P., & ABBRUZZESE, J. (1995). PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE. International Journal of Oncology, 6, 447-450. https://doi.org/10.3892/ijo.6.2.447
MLA
LENZI, R., RABER, M., GRAVEL, D., FROST, P., ABBRUZZESE, J."PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE". International Journal of Oncology 6.2 (1995): 447-450.
Chicago
LENZI, R., RABER, M., GRAVEL, D., FROST, P., ABBRUZZESE, J."PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE". International Journal of Oncology 6, no. 2 (1995): 447-450. https://doi.org/10.3892/ijo.6.2.447